Summary of MoonLake Immunotherapeutics Investor Day Company Overview - **Company Name**: MoonLake Immunotherapeutics - **Founded**: 2021 in Switzerland - **Public Listing**: Nasdaq, went public in April 2022 - **Focus**: Development and commercialization of sonelokimab (SLK), a tri-specific IL-17A and IL-17F inhibiting nanobody targeting large indications in inflammation - **Financial Position**: Well-funded with cash runway into the second half of 2027 and access to a debt facility of up to $400 million [2][3] Product and Clinical Development - **Product**: Sonelokimab (SLK) - **Type**: Nanobody, smaller than traditional antibodies (40 kDa vs. 140-150 kDa) - **Administration**: Subcutaneous injection, 1 mL monthly dosing - **Clinical Trials**: Conducted Phase II and III studies across five large indications in dermatology and rheumatology, including: - Hidradenitis Suppurativa (HS) - Psoriasis (PSO) - Psoriatic Arthritis (PsA) - Axial Spondyloarthritis (axSpA) - **Regulatory Plans**: BLA submission for SLK expected in the second half of 2026, with potential first approval in the US in the second half of 2027 [3][10] Clinical Data Highlights - **S-OLARIS Trial**: Focused on axSpA, showing promising results with high response rates: - Over 80% of patients achieved ASAS40 response by week 8, maintaining high levels by week 12 [17][19] - Significant reduction in bone inflammation measured by SPARCC MRI score, with over 80% reduction observed [20] - Use of innovative imaging techniques (MRI, PET) to assess treatment effects on ossification [21][22] - **Long-term Data**: VELA studies in HS patients show high response rates, with VELA-1 and VELA-2 trials demonstrating competitive efficacy compared to other commercialized drugs [56][57] Market Opportunity - **AxSpA Market**: Estimated market size of $10 billion to $15 billion by 2038, with a conservative growth rate of biologic usage [13] - **HS Market**: Ongoing discussions with the FDA to ensure a competitive label for SLK, leveraging data from VELA studies [25][26] Regulatory Strategy - **FDA Interactions**: Positive feedback received, confirming that no additional clinical trials are required for BLA submission [30][31] - **Label Development**: Focus on establishing substantial evidence of effectiveness (SEE) through VELA-1, VELA-2, and MIRA trials [30][35] - **Competitive Edge**: Emphasis on a clean safety profile and a more convenient dosing regimen compared to competitors [53][54] Key Takeaways - **Innovative Approach**: SLK aims to provide disease modification in axSpA, addressing core disease pathways rather than just symptoms [22][24] - **Strong Clinical Profile**: High response rates and innovative trial designs position SLK favorably against competitors in the IL-17 space [24][52] - **Regulatory Clarity**: Clear guidance from the FDA supports a streamlined path for BLA submission, enhancing investor confidence [35][52] This summary encapsulates the key points discussed during the MoonLake Immunotherapeutics Investor Day, highlighting the company's strategic direction, product development, and market potential.